OverweightPhase 3ENLIGHTEN-6NCT07392190
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Phase 3 study testing Eloralintide in people with Overweight and Obesity, run by Eli Lilly and Company at 185 sites in 14 countries.
Trial summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- Eloralintide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 900 participants
- Where
- 185 sitesin 14 countries
- Study dates
- 10 Feb 2026to Jul 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Are on stable incretin therapy at screening
- With persistent obesity or overweight defined as:
- ≥30 kg/m2 OR
- ≥27 kg/m2 with at least one existing obesity related complication at screening:
- hypertension
- dyslipidemia
Show all 10Show fewer
- obstructive sleep apnea
- cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
- type 2 diabetes
- Have a stable body weight (<5% body weight change) at screening
Who cannot join
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following antihyperglycemic medications within 90 days before screening:
- dipeptidyl peptidase-4 (DPP-4) inhibitors
- amylin analogs
Show all 14Show fewer
- insulin
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Trial locations and contacts
185 sites in 14 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
185 sites in 14 countries
United States58 sites, 58 recruiting
- Recruiting
JEM Research Institute
Atlantis, Florida, 33462
561-968-2933
David Halpert
- Recruiting
Birmingham Clinical Research
Birmingham, Alabama, 35209
205-870-4343
Nova Law
- Recruiting
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts, 02115
617-732-4245
Vanita Aroda
- Recruiting
New England Research Associates, LLC
Bridgeport, Connecticut, 06606
203-374-9816
Ilja Hulinsky
- Recruiting
University of North Carolina Medical Center
Chapel Hill, North Carolina, 27514
984-974-3004
Klara Klein
- Recruiting
Clinical Research Professionals
Chesterfield, Missouri, 63005
636-220-1200
Timothy Jennings
- Recruiting
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
773-275-3500 Ext 162
Rupal Trivedi
- Recruiting
CTI Clinical Research Center
Cincinnati, Ohio, 45212
513-721-3868
Robert Wagner
- Recruiting
Centennial Medical Group
Columbia, Maryland, 21045
410-730-3399
Rajiv Dua
- Recruiting
UT Southwestern Medical Center
Dallas, Texas, 75390
Amy Shah
- Recruiting
AMR Clinical
Doral, Florida, 33172
Abid Chaudhry
- Recruiting
Teak Research Consults - Dunwoody
Dunwoody, Georgia, 30338
470-403-4755
Aakar Thaker
- Recruiting
Northeast Research Institute (NERI)
Fleming Island, Florida, 32003
904-541-8225
Senan Sultan
- Recruiting
Center for Advanced Research & Education
Gainesville, Georgia, 30501
770-534-5154
Angela Ritter
- Recruiting
Medication Management
Greensboro, North Carolina, 27401
336-763-6968
James Franklin
- Recruiting
Juno Research
Houston, Texas, 77040
713-779-5494
Damaris Vega
- Recruiting
Family First Medical Center
Idaho Falls, Idaho, 83404
208-552-7700
Flint Packer
- Recruiting
Irvine Clinical Research
Irvine, California, 92614
949-753-1663
Elly Lee
- Recruiting
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216
904-730-0101
Alpa Patel
- Recruiting
Activian Clinical Research
Kingwood, Texas, 77339
832-969-3401
Martin Basaldua
- Recruiting
Scripps Whittier Diabetes Institute
La Jolla, California, 92037
858-824-5352
Athena Philis-Tsimikas
- Not yet recruiting
EndoTrials Center for Clinical Research
La Mesa, California, 91942
619-460-2626
Darius Schneider
- Recruiting
AMR Clinical
Lexington, Kentucky, 40509
Peter Akpunonu
- Recruiting
Care Access - Lima
Lima, Ohio, 45805
Jimmy Alele
- Recruiting
New Horizon Research Center
Miami, Florida, 33165
305-226-3933
Lazaro Nunez
- Recruiting
Texas Valley Clinical Research (TVCR) - Mission
Mission, Texas, 78572
Alejandro Gonzalez Campos
- Recruiting
Synergy Groups Medical LLC - Missouri City
Missouri City, Texas, 77459
832-532-4210
Deirdre McMullen
- Recruiting
IMA Clinical Research Monroe-Main
Monroe, Louisiana, 71201
318-737-1098
Mark Napoli
- Recruiting
Carteret Medical Group
Morehead City, North Carolina, 28557
252-499-8623
Mary Lawrence
- Not yet recruiting
Trial Management Associates
Myrtle Beach, South Carolina, 29572
843-994-7655
Donald Eagerton
- Recruiting
Yale University School of Medicine
New Haven, Connecticut, 06519
203-785-7421
Ania Jastreboff
- Recruiting
NYU Langone Health
New York, New York, 10016
212-263-3166
Holly Lofton
- Recruiting
Weill Cornell Medical College
New York, New York, 10021
646-962-2111
Louis Aronne
- Recruiting
IMA Clinical Research Manhattan
New York, New York, 10036
Eli Shalenberg
- Recruiting
RIO Clinical Trials - Phoenix
Phoenix, Arizona, 85016
480-966-7882
Kenneth Steil
- Recruiting
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania, 15236
412-650-6155
Bryce Palchick
- Recruiting
Peninsula Research Associates
Rolling Hills Estates, California, 90274
310-265-1623
Lawrence Sher
- Not yet recruiting
Care Access - Sacramento
Sacramento, California, 95831
925-734-2331
Francisco Garcia
- Recruiting
St Johns Center for Clinical Research
Saint Augustine, Florida, 32086
904-209-0043
Ameeth Vedre
- Recruiting
IMA Clinical Research San Antonio
San Antonio, Texas, 78229
210-692-7157
Priscilla Thomas
- Recruiting
Endeavor Clinical Trials
San Antonio, Texas, 78240
518-428-6859
Nitendra Agarwal
- Recruiting
Artemis Institute for Clinical Research
San Diego, California, 92123
858-278-3647
Stacey Layle
- Recruiting
Southern California Clinical Research
Santa Ana, California, 92701
714-474-2173
Wayne Ho
- Recruiting
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
480-725-8708
Benjamin Clark
- Recruiting
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
210-545-4900
Michelle Welch
- Recruiting
Great Lakes Research Institute
Southfield, Michigan, 48075
248-864-5242
Derrick Williamson
- Recruiting
Revive Research Institute, Inc.
Southfield, Michigan, 48075
248-829-3103
Syed Raza
- Recruiting
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
785-354-9591
susan brian
- Recruiting
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
248-312-0025
Neil Fraser
- Recruiting
Novak Clinical Research - Tucson - North La Cholla Boulevard
Tucson, Arizona, 85741
Thili Kulatilake
- Recruiting
University Clinical Investigators, Inc.
Tustin, California, 92780
714-734-7944
Joanna Van
- Recruiting
MedVadis Research Corporation
Waltham, Massachusetts, 02451
617-744-1310
David DiBenedetto
- Recruiting
Chase Medical Research, LLC
Waterbury, Connecticut, 06708
203-419-4420
Joseph Soufer
- Recruiting
Texas Valley Clinical Research
Weslaco, Texas, 78596
956-431-8090
Eduardo Luna
- Recruiting
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50266
Amy Keller
- Recruiting
Metabolic Research Institute, Inc.
West Palm Beach, Florida, 33401
561-802-3060
Barry Horowitz, MD
- Recruiting
Accellacare - Wilmington - 1917 Tradd Court
Wilmington, North Carolina, 28401
910-799-5500
John Parker
- Recruiting
Medrasa Clinical Research
Wylie, Texas, 75098
469-449-3645
Tanvir Ahmad
China22 sites, 22 recruiting
- Not yet recruiting
The First Hospital of Jilin University
Changchun, 130021
15843081103
Guixia Wang
- Recruiting
The Second Hospital of Jilin University
Changchun, 130041
Hanqing Cai
- Recruiting
The Second Xiangya Hospital of Central South University
Changsha, 410011
Xia Li
- Recruiting
Sichuan Provincial People's Hospital
Chengdu, 610072
Limin Tian
- Recruiting
West China Hospital Sichuan University
Chengdu, 610041
18980601658
zhenmei an
- Not yet recruiting
2nd Affiliated Hospital Chongqing Medical Universi
Chongqing, 400000
13594028475
Dongfang Liu
- Recruiting
Zhujiang Hospital
Guangzhou, 510280
Jia Sun
- Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, 550004
Miao Zhang
- Recruiting
The Second People's Hospital of Hefei
Hefei, 230011
86-13956099720
Jun Ye
- Recruiting
Huzhou Central Hospital
Huzhou, 313000
Shunbin Li
- Not yet recruiting
Jinan Central Hospital
Jinan, 250013
Nianrong Mi
- Recruiting
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471023
13653880139
Hongwei Jiang
- Recruiting
Affiliated Hospital of Luzhou Medical College
Luzhou, 646000
Qin Wan
- Recruiting
Jiangxi Provincial People's Hospital
Nanchang, 330038
13767035719
Zongyou Cheng
- Recruiting
Nanjing First Hospital
Nanjing, 210006
15366136156
Qian Li
- Recruiting
Zhongda Hospital Southeast University
Nanjing, 210009
Ling Li
- Recruiting
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210011
18951762960
Yibing Lu
- Recruiting
Ningbo First Hospital
Ningbo, 315010
13757426626
Li Li
- Not yet recruiting
Zhongshan Hospital,Fudan University
Shanghai, 200032
13651913857
Xiaoying Li
- Not yet recruiting
The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Wenzhou, 315100
13806542929
Chaoming Wu
- Recruiting
The Central Hospital of Wuhan
Wuhan, 430014
Zhongjing Wang
- Not yet recruiting
Xianyang Hospital of Yan'an University
Xianyang, 712000
18391081568
Fang Wang
Israel17 sites, 17 recruiting
- Not yet recruiting
Emek Medical Center
Afula, 1834111
97246495139
Lee Goldstein
- Not yet recruiting
Clalit Health Services - Atlit
Atlit, 3032301
04-9842020
Elie Haddad
- Not yet recruiting
Soroka Medical Center
Beersheba, 8410101
972-8-6403896
Idit Liberty
- Not yet recruiting
Hillel Yaffe Medical Center
Hadera, 3810101
04-7744931
Irit Hochberg
- Not yet recruiting
Rambam Health Care Campus
Haifa, 3109601
972-4-7771606
Sagit Zolotov
- Not yet recruiting
Edith Wolfson Medical Center
Holon, 5810001
972-35028392
Orit Twito
- Not yet recruiting
Hadassah Medical Center
Jerusalem, 9112001
+972-507874590
Gil Leibowitz
- Not yet recruiting
Meir Medical Center
Kfar Saba, 4428164
972-97472559
Victor Vishlitzky
- Not yet recruiting
Maccabi health care services - Qiryat Motzkin
Kiryat Motzkin, 2642435
+97248781555
Afif Nakhleh
- Not yet recruiting
Laniado Hospital
Netanya, 4244914
+97298609325
Mark Niven
- Not yet recruiting
Rabin Medical Center - Hasharon Campus
Petah Tikva, 4937211
972-3-9372429
Dror Dicker
- Not yet recruiting
Rabin Medical Center
Petah Tikva, 4941492
+97239377183
Idit Dotan
- Not yet recruiting
Sheba Medical Center
Ramat Gan, 5262100
97235302021
Gabriella Segal Lieberman
- Not yet recruiting
Kaplan Medical Center
Rehovot, 7610001
9729441895
Viviana Ostrovsky
- Not yet recruiting
Clalit Health Services - Sakhnin Community Clinic
Sakhnin, 3081000
97246745729
Mahmud Darawsha
- Not yet recruiting
Diabetes Medical Center
Tel Aviv, 51549
97236900333
Maya Ish Shalom
- Not yet recruiting
Sourasky Medical Center
Tel Aviv, 6423906
97236973415
Yael Sofer
Japan11 sites, 11 recruiting
- Recruiting
The Institute of Medical Science, Asahi Life Foundation
Chūōku, 103-0002
81120023812
Yukiko Onishi
- Recruiting
Rinku General Medical Center
Izumisano, 598-8577
81120023812
Tomoko Otsuki
- Recruiting
Kanto Rosai Hospital
Kawasaki, 211-8510
81120023812
Yoshio Nagai
- Recruiting
Kimitsu Chuo Hospital
Kisarazu, 292-8535
81120023812
Ryoichi Ishibashi
- Recruiting
Kure Medical Center
Kure, 737-0023
81120023812
Mitsunobu Kubota
- Recruiting
Takeda General Hospital - Kyoto
Kyoto, 601-1495
81120023812
KIminori Hosoda
- Recruiting
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, 7900034
81120023812
Tetsuji Niiya
- Recruiting
Kansai Electric Power Hospital
Osaka, 553-0003
81120023812
Yoshiyuki Hamamoto
- Recruiting
Manda Memorial Hospital
Sapporo, 060-0062
81120023812
Masahiko Kato
- Recruiting
Shimonoseki Medical Center
Shimonoseki, 750-0061
81120023812
Kaoru Noda
- Recruiting
Japanese Red Cross Society - Wakayama Medical Center
Wakayama, 640-8558
81120023812
Shizuka Kaneko
Australia10 sites, 10 recruiting
- Recruiting
Emeritus Research
Botany, 2019
Paul Bird
- Recruiting
Box Hill Hospital
Box Hill, 3128
Ming Li Yee
- Recruiting
Royal Brisbane and Women's Hospital
Brisbane, 4029
+61736468111
Donald McLeod
- Recruiting
Emeritus Research
Camberwell, 3124
Sam Francis
- Recruiting
Barwon Health
Geelong, 3220
Kay Hau (Aaron) Choy
- Recruiting
Austin Health - Repatriation Hospital
Heidelberg West, 3081
0394962160
Elif Ekinci
- Recruiting
AIM Research
Merewether, 2291
+61 2 4963 2323
Claire Morbey
- Recruiting
Southern Adelaide Diabetes & Endocrine Services
Oaklands Park, 5046
0874258693
Jui Ho
- Recruiting
Royal North Shore Hospital
St Leonards, 2065
Sarah Glastras
- Recruiting
Innovate Clinical Research
Waitara, 2077
Rachel Graham
India10 sites
- Suspended
Motilal Nehru Medical College Hospital
Allahabād, 211002
- Suspended
Life Care Hospital and Research Centre
Bangalore, 560092
- Suspended
Madras Diabetes Research Foundation
Chennai, 600086
- Suspended
Nizam's Institute of Medical Sciences
Hyderabad, 500082
- Suspended
Eternal Heart Care Center and Research Institute
Jaipur, 302020
- Suspended
Atmaram Child Care
Kanpur, 208011
- Suspended
Shree Mahalaxmi DIATONE Institute
Kolhāpur, 416001
- Suspended
Mysore Medical College
Mysore, 570001
- Suspended
All India Institute of Medical Sciences (AIIMS) - Nagpur
Nagpur, 441108
- Suspended
Nirmal Hospital Pvt Ltd.
Surat, 395002
Romania10 sites, 10 recruiting
- Recruiting
Mariodiab Clinic
Brasov, 500097
40721203324
Brindusa Cofaru
- Recruiting
C.M.D.T.A. Neomed
Brasov, 500283
0040762249010
Liliana Marin
- Recruiting
Geea Medical Easy Diet
Bucharest, 010627
40314288633
Georgeta Vacaru
- Recruiting
Centrul Medical NutriLife
Bucharest, 013764
0040212323445
Marlena Pascu
- Recruiting
Gama Diamed
Mangalia, 905500
0040241740581
Amalia Thury-Burileanu
- Recruiting
Diabdana
Oradea, 410147
004 0722 480 224
Dana Cosma
- Recruiting
Clinica Korall
Satu Mare, 440055
40746013882
Adriana Filimon
- Recruiting
Rinart Diab SRL
Targoviste, 130168
0040724372432
Anca Nicoara
- Recruiting
SC Dentosim Queen SRL - Centrul Medical Diamed
Târgu Mureş, 540098
0040745641194
Daniela Ciomos
- Recruiting
Cabinet Medical Dr.Geru
Timișoara, 300288
0723377127
Polina Geru
Spain10 sites, 10 recruiting
- Recruiting
Hospital San Rafael - La Coruña
A Coruña, 15006
655624017
Alfonso Soto Gonzalez
- Recruiting
Centro Periférico de Especialidades Bola Azul
Almería, 04009
0034678510067
Pedro Mezquita-Raya
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
34697817352
ANDREEA CIUDIN
- Recruiting
Instituto Gallego de Cirugía Ocular
Ferrol, 15402
Alma Maria Prieto tenreiro
- Recruiting
Clínica Juaneda
Palma de Mallorca, 07014
34 871 205256
Santiago Tofe Povedano
- Recruiting
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, 28223
34914522000
Esteban Jodar Gimeno
- Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, 39008
34639659866
Luis Vazquez Salvi
- Recruiting
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, 41003
+ 34 954709183
Alberto Aliaga Verdugo
- Recruiting
Hospital Quiron Infanta Luisa
Seville, 41010
670502836
MARGARITA RIVAS FERNANDEZ
- Recruiting
Vithas Hospital Sevilla
Seville, 41950
658011529
Cristobal Morales Portillo
Belgium9 sites, 9 recruiting
- Recruiting
Imelda General Hospital
Bonheiden, 2820
003215505164
Chris Vercammen
- Recruiting
Université Libre de Bruxelles - Hôpital Erasme
Brussels, 1070
Laurent Crenier
- Recruiting
Ziekenhuis Oost-Limburg, Campus St.-Jan
Genk, 3600
3289807250
David Verhaert
- Recruiting
Jan Yperman Ziekenhuis
Ieper, 8900
+3257357270
An Nollet
- Recruiting
AZ Groeninge Campus Kennedylaan
Kortrijk, 8500
003256633180
Gerd Vanhaverbeke
- Recruiting
UZ Leuven
Leuven, 3000
3216346994
Roman Vangoitsenhoven
- Recruiting
AZ Sint-Maarten
Mechelen, 2800
+3215892042
Michel Vandenbroucke
- Recruiting
Meclinas
Mechelen, 2800
003215792797
Julie Casaer
- Recruiting
Az Damiaan vzw
Ostend, 8400
059414160
Marianne Kerrebrouck
Taiwan9 sites, 9 recruiting
- Recruiting
Chiayi Christian Hospital
Chiayi City, 600
886-5-2765041
Chu-Kuang Chou
- Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 807
886-7-3121101 ext 7741
Tsung-Hsien Lin
- Recruiting
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, 83301
+886912159389
Jung-Fu Chen
- Recruiting
China Medical University Hospital
Taichung, 404332
886923832500
Wen-Yuan Lin
- Recruiting
National Cheng Kung University Hospital
Tainan, 704
886 62353535 ext 3985
Yi-Ching Yang
- Recruiting
National Taiwan University Hospital
Taipei, 10002
0223123456
Chih-Yuan Wang
- Recruiting
Taipei Medical University Hospital
Taipei, 110
886-2-2737-2181 ext 8481
Chun-Yao Huang
- Recruiting
Taipei Veterans General Hospital
Taipei, 11217
886228757516
Chii-Min Hwu
- Recruiting
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
Chia-Hung Lin
Brazil7 sites, 7 recruiting
- Not yet recruiting
Quanta Diagnóstico e Terapia
Curitiba, 80045170
5541999736442
Rosangela Rea
- Not yet recruiting
Centro de Diabetes Curitiba
Curitiba, 80810-040
554130231252
LUCIANA PECHMANN
- Not yet recruiting
Private Practice - Dr.Miguel N. Hissa
Fortaleza, 60430-350
55 85 3214.6530
Miguel Hissa
- Not yet recruiting
CPCLIN
São Paulo, 01228-200
551126303777
Denise Franco
- Not yet recruiting
Hospital 9 De Julho
São Paulo, 01409-901
551131479432
Layana Sandes Fraga
- Not yet recruiting
CEDOES
Vitória, 29055450
55 27 99933-3330
Queulla Santos
- Not yet recruiting
Integral Pesquisa e Ensino
Votuporanga, 15500-269
55017997472217
GRACIELLY DE SOUZA PANTANO
Mexico7 sites, 7 recruiting
- Not yet recruiting
Medical Center Metas
Chihuahua City, 31110
52 614 423 5956
Luis Nevarez
- Not yet recruiting
Private Practice - Dr. Arechavaleta Granell Maria del Rosario
Guadalajara, 44670
523336165410 400
Maria Arechavaleta Granell
- Not yet recruiting
Invecordis S.C.
Huixquilucan, 52763
52 55 9185 9959
Luisa Villanueva-Rodríguez
- Not yet recruiting
Centro de Investigacion en Artritis y Osteoporosis SC
Mexicali, 21200
686 5534121
Francisco Lopez Maldonado
- Not yet recruiting
Gastrobariátrica Santa Fe
Mexico City, 05348
Juan Mauricio Vera Zertuche
- Not yet recruiting
CEINV Salud
Monterrey, 64020
52 8141916867
Jose Gerardo González González
- Not yet recruiting
Clínica García Flores SC
Monterrey, 64610
528113578379
Pedro García Hernández
Czechia3 sites, 3 recruiting
- Recruiting
Diahaza s.r.o.
Holešov, 769 01
420573399559
Jitka Hasalova Zapletalova
- Recruiting
Milan Kvapil s.r.o., Diabetologicka ambulance
Prague, 14900
420272917011
Frantisek Loos
- Recruiting
ResTrial s.r.o.
Prague, 18100
420257211886
Emilia Malicherova
Puerto Rico2 sites, 2 recruiting
- Recruiting
Advanced Clinical Research, LLC
Bayamón, 00959
7872696590
Angel Comulada-Rivera
- Recruiting
Isis Clinical Research Center
Guaynabo, 00968
7874045252
Paola Mansilla-Letelier
About this study
Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
- Conditions
- Overweight, Obesity
- Being tested
- Eloralintide, Placebo
- Keywords
- Amylin receptor agonist
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EloralintideDrug
Also called LY3841136
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Eloralintide Dose 1 | Experimental | Participants will receive eloralintide subcutaneously (SC) Receives: Drug: Eloralintide |
| Eloralintide Dose 2 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Eloralintide Dose 3 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Eloralintide Dose 4 | Experimental | Participants will receive eloralintide SC Receives: Drug: Eloralintide |
| Placebo | Placebo comparator | Participants will receive placebo SC Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 64
Secondary outcomes (15)
Change from Baseline in Waist Circumference
Measured: Baseline, Week 64
Percent Change in Baseline in Triglycerides
Measured: Baseline, Week 64
Change from Baseline in Systolic Blood Pressure
Measured: Baseline, Week 64
Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 64
Change from Baseline in Fasting Glucose in Participants with Type 2 Diabetes at Baseline
Measured: Baseline, Week 64
Change from Baseline in Short Form-36 (SF-36 v2) Score
Measured: Baseline, Week 64
Change from Baseline in EQ-5D-5L Score
Measured: Baseline, Week 64
Change from Baseline in Control of Eating Questionnaire (CoEQ) Score
Measured: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Measured: Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Measured: Baseline, Week 64
Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP)
Measured: Baseline, Week 64
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Measured: Baseline, Week 64
Change in Medication Use
Measured: Baseline through Week 64
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)
Measured: Baseline through Week 64
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Measured: Baseline through Week 64
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2026
- Study start10 Feb 2026
- Primary completionJun 2028 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07392190
- Sponsor's protocol ID
- 27743
- Other IDs
- J3R-MC-YDAL, 2025-523659-73-00, 2025
- Acronym
- ENLIGHTEN-6
- Status last verified
- Nov 2026
- First submitted
- 30 Jan 2026
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07392190
- Acronym / sponsor ID
- ENLIGHTEN-6 / 27743
- Conditions
- Overweight, Obesity
- Keywords
- Amylin receptor agonist
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 10 Feb 2026 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 6 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Eloralintide Dose 1 | Experimental | Drug: EloralintideParticipants will receive eloralintide subcutaneously (SC) |
| Eloralintide Dose 2 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Eloralintide Dose 3 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Eloralintide Dose 4 | Experimental | Drug: EloralintideParticipants will receive eloralintide SC |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo SC |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Are on stable incretin therapy at screening
- With persistent obesity or overweight defined as:
- Have a stable body weight (<5% body weight change) at screening
Key exclusion criteria (14 listed)
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following antihyperglycemic medications within 90 days before screening:
- Have had within 90 days prior to screening:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EloralintideAlso: LY3841136Administered SC | Drug | Eloralintide Dose 1, Eloralintide Dose 2, Eloralintide Dose 3, Eloralintide Dose 4 |
| PlaceboAdministered SC | Drug | Placebo |
Primary outcome
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 64
15 secondary outcomes
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 64
Percent Change in Baseline in Triglycerides
Time frame: Baseline, Week 64
Change from Baseline in Systolic Blood Pressure
Time frame: Baseline, Week 64
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 64
Change from Baseline in Fasting Glucose in Participants with Type 2 Diabetes at Baseline
Time frame: Baseline, Week 64
Change from Baseline in Short Form-36 (SF-36 v2) Score
Time frame: Baseline, Week 64
Change from Baseline in EQ-5D-5L Score
Time frame: Baseline, Week 64
Change from Baseline in Control of Eating Questionnaire (CoEQ) Score
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) Physical Function Weight
Time frame: Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 64
Percent Change from Baseline in High Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 64
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 64
Change in Medication Use
Time frame: Baseline through Week 64
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)
Time frame: Baseline through Week 64
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 64
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6)Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
185 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Eloralintide in people with Overweight and Obesity, run by Eli Lilly and Company at 185 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 185 sites in United States, China, Israel, Japan, Australia and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change from Baseline in Body Weight (time frame: Baseline, Week 64). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.